A Bioinformatics-Based Analysis of an Anoikis-Related Gene Signature Predicts the Prognosis of Patients with Low-Grade Gliomas.
Songyun ZhaoHao ChiWei JiQisheng HeGuichuan LaiGaoge PengXiaoyu ZhaoChao ChengPublished in: Brain sciences (2022)
Low-grade glioma (LGG) is a highly aggressive disease in the skull. On the other hand, anoikis, a specific form of cell death induced by the loss of cell contact with the extracellular matrix, plays a key role in cancer metastasis. In this study, anoikis-related genes (ANRGs) were used to identify LGG subtypes and to construct a prognostic model for LGG patients. In addition, we explored the immune microenvironment and enrichment pathways between different subtypes. We constructed an anoikis-related gene signature using the TCGA (The Cancer Genome Atlas) cohort and investigated the differences between different risk groups in clinical features, mutational landscape, immune cell infiltration (ICI), etc. Kaplan-Meier analysis showed that the characteristics of ANRGs in the high-risk group were associated with poor prognosis in LGG patients. The risk score was identified as an independent prognostic factor. The high-risk group had higher ICI, tumor mutation load (TMB), immune checkpoint gene expression, and therapeutic response to immune checkpoint blockers (ICB). Functional analysis showed that these high-risk and low-risk groups had different immune statuses and drug sensitivity. Risk scores were used together with LGG clinicopathological features to construct a nomogram, and Decision Curve Analysis (DCA) showed that the model could enable patients to benefit from clinical treatment strategies.
Keyphrases
- low grade
- prognostic factors
- gene expression
- poor prognosis
- end stage renal disease
- cell death
- high grade
- newly diagnosed
- ejection fraction
- extracellular matrix
- dna methylation
- single cell
- emergency department
- stem cells
- long non coding rna
- genome wide
- patient reported outcomes
- papillary thyroid
- decision making
- bone marrow
- angiotensin ii
- squamous cell
- pi k akt
- mesenchymal stem cells